7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing...

Details 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing... 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing...

2004-07-06

2009-11-03

Aulakh, Charanjit S (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S048000, C435S184000

Reexamination Certificate

active

07612081

ABSTRACT:
Compounds are disclosed with the general formulain which the groups are as defined in the description here below and characterized by the presence of polyamine substituents on the imine/oxime residue, such amine groups being in turn protected by suitable protective groups. Said compounds are endowed with potent topoisomerase I inhibiting activity and therefore are useful as medicaments for the treatment of tumors and viral and parasite infections.

REFERENCES:
patent: 6242457 (2001-06-01), Penco et al.
patent: 6589939 (2003-07-01), Penco et al.
patent: 7105492 (2006-09-01), Dallavalle et al.
patent: 2001/0008939 (2001-07-01), Penco et al.
patent: 1 044 977 (2000-10-01), None
patent: 97/00876 (1997-01-01), None
patent: 03/101995 (2003-12-01), None
patent: 2004/083214 (2004-09-01), None
International Search Report for PCT/IT2004/000374 dated Dec. 21, 2004.
Dallavalle et al.,Novel Cytotoxic 7-Iminomethyl and 7-Aminomethyl Derivatives of Camptothecin, Bioorg. Med. Chem. Lett., vol. 11, 2001, pp. 291-294, XP002286415.
Dallavalle et al.,Perspectives in camptothecin development, Expert. Opin. Ther. Patents, vol. 12, No. 6, 2002, pp. 837-844, XP002251117.
Dallavalle et al.,Novel 7-Oxyiminomethyl Derivatives of Camptothecin with Potent in Vitro and in Vivo Antitumor Activity, J. Med. Chem., vol. 44, No. 20, May 9, 2001, pp. 3264-3274, XP002307863.
Horwitz et al, “Antiviral Action of Camptothecin”, Antimicrobial Agents and Chemotherapy, Nov. 1972, pp. 395-401.
Li et al, “Three Inhibitors of Type 1 Human Immunodeficiency Virus Long Terminal . . . ”, Proc. Natl. Acad. Sci. USA, vol. 99, pp. 1839-1842, Mar. 1993.
Garcia-Carbonero et al, “Current Perspectives on the Clinical Experience, Pharmacology . . . ”, Clinical Cancer Research, vol. 8, 641-661, Mar. 2002.
Dallavalle et al, “Perspectives in Camptothecin Development”, Expert Opinion Ther. Patents (2002) 12(6) 837; XP-002251117.
Lesueur-Ginot et al, “Homocamptothecin, an E-Ring Modified Camptothecin . . . ”, Cancer Research 59, 2939-2943, Jun. 15, 1999.
Vladu et al, “7- and 10-Substituted Camptothecins: Dependence of Topoisomerase . . . ”, Molecular Pharmacology, 57:243-251 (2000).
Dallavalle et al, “Novel 7-Oxyiminomethyl Derivatives . . . ”, J. Med. Chem. 2001, 44, 3264-3274.
Kantarjian et al, “Phase I Study of Topotecan, A New Topoisomerase . . . ”, Blood, vol. 81, No. 5 (Mar. 1, 1993), pp. 1146-1151.
Kaufmann et al, “Topoisomerase II Levels and Drug Sensitivity . . . ”, Blood, vol. 83, No. 2 (Jan. 15, 1994): pp. 517-530.
Lichtman et al, “Chemotherapy in the Elderly . . . ”, Cancer Control, Nov./Dec. 2000, vol. 7, No. 6., pp. 548-556.
Bodley et al, “Molecular and Cytotoxic Effects . . . ”, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 3726-3730, Apr. 1995.
Priel et al, “The Topoisomerase I Inhibitor . . . ”, Journal of Virology, Aug. 1991, p. 4137-4141.
Lavergne et al, “Homocamptothecins: Synthesis and Antitumor Activity . . . ”, J. Med. Chem. 1998, 41, 5410-5419.

Affiliated with

Also associated with

Rating

7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4118512